Health Condition 1: C349- Malignant neoplasm of unspecifiedpart of bronchus or lung
Conditions
Interventions
Intervention1: Amivantamab: Participants will receive amivantamab 1050mg intravenously for body weight less than 80kg and 1400 mg for body weight greater than or equal to 80 kg in 28-day cycles: once
Sponsors
Johnson and Johnson Private Limited
Eligibility
Inclusion criteria
Inclusion criteria: - Participant must have histologically or cytologically confirmed, locally advanced or metastatic non-small cell lung cancer (NSCLC) not amenable to curative therapy - Participant must have a tumor that was previously determined to have exon 19 deletions (Exon 19del) or Exon 21 L858R substitution, as detected by an food and drug administration (FDA)-approved or other validated test in a clinical laboratory improvement amendments (CLIA) certified laboratory (sites in the United states [US]) or an accredited local laboratory (sites outside of the US) in accordance with site standard of care. The biopsy must have been obtained at or after the diagnosis of advanced disease - Unstained tumor tissue (in a quantity sufficient to allow for central analysis of epidermal growth factor receptor (EGFR) mutation status, see Laboratory Manual) and blood (for circulating tumor deoxyribonucleic acid [ctDNA], digital droplet polymerase chain reaction [ddPCR], and pharmacogenomic analysis), both collected at or after the diagnosis of locally advanced or metastatic NSCLC, must be provided - Any toxicities from prior anticancer therapy must have resolved to common terminology criteria for adverse events (CTCAE) Grade 1 or baseline level - Participant must have at least 1 measurable lesion, according to response evaluation criteria in solid tumors (RECIST) v1.1 that has not been previously irradiated. Measurable lesions should not have been biopsied during screening, but if only 1 non-irradiated measurable lesion exists, it may undergo a diagnostic biopsy and be acceptable as a target lesion, provided the baseline tumor assessment scans are performed at least 14 days after the biopsy
Exclusion criteria
Exclusion criteria: - Participant has received any prior systemic treatment for locally advanced or metastatic disease (adjuvant or neoadjuvant therapy is allowed, if administered more than 12 months prior to the development of locally advanced or metastatic disease) - Participant has an active or past medical history of leptomeningeal disease - Participant has spinal cord compression that has not been definitively treated with surgery or radiation or requires steroid treatment within 2 weeks prior to randomization - Participant has an active or past medical history of interstitial lung disease (ILD)/pneumonitis, including drug-induced or radiation ILD/pneumonitis - Participant has known allergy, hypersensitivity, or intolerance to the excipients used in formulation of amivantamab, lazertinib, or osimertinib, or any contraindication to the use of osimertinib - Participant has symptomatic brain metastases. A participant with asymptomatic or previously treated and stable brain metastases may participate in this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-Free Survival according to RECIST v1.1 by Blinded Independent Central ReviewTimepoint: Up to approximately 42 months | — |
Secondary
| Measure | Time frame |
|---|---|
| Change from Baseline in European Organization of Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC-QLQ-C30)Timepoint: Baseline Up to approximately 42 months;Change from Baseline in Non-Small Cell Lung Cancer -Symptom Assessment Questionnaire (NCSLC-SAQ)Timepoint: Baseline Up to approximately 42 months;Duration of ResponseTimepoint: Up to approximately 42 months;Incidence and Severity of Adverse EventsTimepoint: Up to approximately 60 months;Intracranial PFSTimepoint: Up to approximately 42 months;Number of Participants with Anti-Amivantamab AntibodiesTimepoint: Up to approximately 42 months;Number of Participants with Clinical Laboratory AbnormalitiesTimepoint: Up to approximately 60 months;Number of Participants with Physical Examination AbnormalitiesTimepoint: Up to approximately 60 months;Number of Participants with Vital Signs AbnormalitiesTimepoint: Up to approximately 60 months;Objective Response RateTimepoint: Up to approximately 42 months;Overall SurvivalTimepoint: Up to approximately 60 months;Plasma Concentration of LazertinibTimepoint: Up to approximately 42 months;Progression-Free Survival After First Subsequent TherapyTimepoint: Up to approximately 42 months;Serum Concentration of AmivantamabTimepoint: Up to approximately 42 months;Time to Symptomatic ProgressionTimepoint: Up to approximately 42 months | — |
Countries
Australia, Belarus, Belgium, Brazil, Canada, China, France, Germany, Hong Kong, Hungary, India, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, Poland, Portugal, Republic of Korea, Russian Federation, Spain, Taiwan, Thailand, Turkey, Ukraine, United Kingdom, United States of America
Contacts
Public ContactDr Sanish Davis
Janssen Pharmaceutical Companies of Johnson & Johnson
Outcome results
None listed